SNP 610

Drug Profile

SNP 610

Alternative Names: SNP-610

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sinew Pharma
  • Class Hepatoprotectants; Immunoconjugates
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Non-alcoholic steatohepatitis

Most Recent Events

  • 19 Jul 2017 SNP 610 is available for licensing as of 19 Jul 2017. http://www.sinewpharma.com/en/product_description.php?pno=1
  • 19 Jul 2017 Sinew Pharma announces intention to submit applications for orphan drug designation, fast track designation and breakthrough designation to US FDA (Sinew Pharma pipeline, July 2017)
  • 19 Jul 2017 Sinew Pharma plans a phase IIa (proof-of-concept) trial for Non alcoholic steatohepatitis in Taiwan (Sinew Pharma pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top